- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04163081
El estudio INITIATE: Inicio del tratamiento de la dependencia de la nicotina para fumadores ingresados en los departamentos de emergencia (INITIATE)
The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Evyanne Wooding, R.Kin
- Número de teléfono: 17596 613-696-7000
- Correo electrónico: ewooding@ottawaheart.ca
Copia de seguridad de contactos de estudio
- Nombre: Chantelle Masterson, BPhil
- Número de teléfono: 19157 613-696-7000
- Correo electrónico: cmasterson@ottawaheart.ca
Ubicaciones de estudio
-
-
Ontario
-
Ottawa, Ontario, Canadá
- Reclutamiento
- University of Ottawa Heart Institute
-
Contacto:
- Dr. Kerri-Anne Mullen
- Número de teléfono: 613-696-7000 ext.19095
- Correo electrónico: KMullen@ottawaheart.ca
-
Ottawa, Ontario, Canadá
- Reclutamiento
- Civic Hospital
-
Contacto:
- Dr. Venkatesh Thiruganasambandamoorthy
- Número de teléfono: 6137985555,17023
- Correo electrónico: vthirug@toh.ca
-
Ottawa, Ontario, Canadá
- Reclutamiento
- General Hospital
-
Contacto:
- Dr. Venkatesh Thiruganasambandamoorthy
- Número de teléfono: 6137985555,17023
- Correo electrónico: vthirug@toh.ca
-
Ottawa, Ontario, Canadá
- Reclutamiento
- Riverside Hospital
-
Contacto:
- Dr. Venkatesh Thiruganasambandamoorthy
- Número de teléfono: 6137985555,17023
- Correo electrónico: vthirug@toh.ca
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Current daily smoker (smokes ≥ 5 cigarettes per day);
- ≥ 18 years of age (the age of majority in Ontario);
- For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
- Able to read and understand English or French;
- Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
- Available and willing to participate in follow-up assessments over the next 12 months;
- Has access to a telephone or computer;
- Able to provide informed consent
Exclusion Criteria:
- Currently participating in this or another smoking cessation study;
- For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
- Pregnant, planning to become pregnant over the next year, or breastfeeding;
- Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
- In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
- Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Quit Card Intervention (QCI)
Study intervention group. |
The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist. |
|
Sin intervención: Usual Care (UC)
Study control group. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Smoking Abstinence
Periodo de tiempo: 26 weeks (6 months) after study enrollment
|
Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test |
26 weeks (6 months) after study enrollment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Prolonged Abstinence
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Point Prevalence Abstinence
Periodo de tiempo: 4, and 52 weeks after study enrollment
|
Point prevalence smoking abstinence, at 4, and 52 weeks |
4, and 52 weeks after study enrollment
|
|
Smoking Reduction
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Number of Quit Attempts
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Number of quit attempts since study entry, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cessation Medication and/or E-cigarette Use
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Use of Behavioural Supports
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health-Related Quality of Life
Periodo de tiempo: 52 weeks after study enrollment
|
Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
52 weeks after study enrollment
|
|
Health Services Outcomes - ED visits
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Hospital Admissions
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Deaths
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cost-Effectiveness Ratios
Periodo de tiempo: 52 weeks after study enrollment
|
Cost-effectiveness ratios related to health services at 52 weeks |
52 weeks after study enrollment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kerri-Anne Mullen, PhD, Ottawa Heart Institute Research Corporation
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 20190485-01H
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .